// App-Quantinova.ai

DOP026 : Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open

Researchers

Presenter

  • B E Sands

Principal Investigators

  • A C Moss

  • A Armuzzi

  • J K Marshall

  • J O Lindsay

  • W J Sandborn

  • S Danese

  • K Tsilkos

  • N Lawendy

  • H Zhang

  • G S Friedman

  • G Chan

  • D W Krichbaum

Medical Centers

  • Icahn School of Medicine at Mount Sinai, The Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States

  • Beth Israel Deaconess Medical Center, Gastroenterology, Boston, USA

  • Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica, Rome, Italy

  • McMaster University, Division of Gastroenterology, Department of Medicine, Farncombe Family Digestive Health Research Institute, Hamilton, ON, Canada

  • The Royal London Hospital, Barts Health NHS Trust, Department of Gastroenterology, London, UK

  • University of California San Diego, Division of Gastroenterology, La Jolla, CA, USA

  • Humanitas Research Hospital, IBD Center, Gastroenterology, Rozzano, Milan, Italy

  • Pfizer Inc, New York, NY

  • Pfizer Inc, Collegeville, PA

Locations

  • United States

  • Italy

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Tasocitinib

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • NA

Study Id's

  • NCT01470612

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved